Defence Therapeutics: Making a Global Impact

October 26, 2022

Stocks to Invest in: Healthcare

Defence Therapeutics is a Canadian Biotech company developing next generation biopharmaceutical innovations for various immuno-oncology (IO) and infectious diseases (ID) indications.

The company is located in Quebec, and their leadership team brings extensive eperience in the capital markets, finance, biochemistry, pharmacology, biotech, immunology.

Their platform is known as ACCUM, which is suitable to enhance the delivery of proteins, RNA and DNA.

Accum is overcoming problematic cell recycling and rejection patterns, ACCUM™ is the first solution to enable ADCs to control intracellular delivery of chemotherapeutic drugs, resulting in superior pre-clinical anti-tumor activity.

For more information on Defence Therapeutics Inc. (CSE: DTC, OTC: DTCFF) please click the request investor info button.


You might also like

Healthcare
Lexaria Bioscience: Revolutionizing GLP-1 Drug Delivery with Patented Oral Platform

Lexaria Bioscience is setting new standards in drug delivery with its patented DehydraTECH™ oral technology, optimizing absorption for GLP-1 and other high-demand drugs.

Healthcare
Lexaria Bioscience: Advancing GLP-1 Drug Delivery with DehydraTECH™ Technology

Lexaria Bioscience’s DehydraTECH™ technology aims to redefine oral drug delivery, focusing on faster absorption and improved efficacy, with a promising impact on the GLP-1 pharmaceutical market.

Content Broadcast on: BNN Bloomberg, CNBC, Bloomberg, FOX Business News, BIZTV, Reuters, The Globe and Mail, YouTube and more!